SCHEDULE: Vanguard Discloses 5.23% Stake in Rani Therapeutics

The Vanguard Group has reported a 5.23% beneficial ownership stake in Rani Therapeutics Holdings Inc. common stock as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 5,109,368 shares of Rani Therapeutics Holdings Inc. common stock.
• This stake represents 5.23% of the total class of securities.
• Vanguard holds shared voting power over 486,801 shares and shared dispositive power over all 5,109,368 shares.
• The filing notes an internal realignment at The Vanguard Group, Inc. effective January 12, 2026, after which it will no longer perform portfolio management or administer proxy voting, with subsidiaries expected to report beneficial ownership separately.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, primarily due to the presence of a major institutional investor, which can lend stability and liquidity to the stock. However, as a passive investment, it doesn't imply a strong conviction in specific company-driven catalysts.

Positives

• The disclosure of a significant stake (5.23%) by a major institutional investor like The Vanguard Group can signal a baseline level of institutional confidence in Rani Therapeutics.
• The certification that shares were acquired in the ordinary course of business and not for control purposes indicates a passive investment, which typically implies stability rather than activist pressure.

Management Comments

• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional ownership by major asset managers like The Vanguard Group is a common occurrence for publicly traded companies, particularly those included in broad market indices. For a biotechnology company like Rani Therapeutics, a significant stake from a passive investor like Vanguard typically reflects inclusion in such indices rather than a specific strategic investment thesis unique to Rani's pipeline or market position. The internal realignment at Vanguard is an operational change for the fund manager, not directly impacting Rani Therapeutics' operations or strategy.

Stakeholder Impact

• Shareholders: Increased institutional ownership can enhance liquidity and potentially reduce volatility. It may also be seen as a vote of confidence, attracting other investors.
• Management: The presence of a large, passive institutional investor typically implies less direct pressure on day-to-day operations, as Vanguard certifies its stake is not for control purposes.

Key Dates

Keywords

Rani Therapeutics, Vanguard Group, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Investment Adviser, Biotechnology, Pharmaceuticals